Drug Profile
Research programme: cancer therapeutics - Molecular Templates
Alternative Names: 3F7; 5G2; MT 2289; MT 4019; MT 6868; MT-2274; MT-6020; MT-6035; MT-SAM3Latest Information Update: 28 Jul 2023
Price :
$50
*
At a glance
- Originator Molecular Templates
- Class Antineoplastics; Bacterial toxins; Drug conjugates; Recombinant proteins; Small interfering RNA
- Mechanism of Action CD38 antigen inhibitors; Immunostimulants; Programmed cell death-1 ligand-1 inhibitors; Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
- No development reported Hodgkin's disease; Malignant melanoma; Multiple myeloma
Most Recent Events
- 28 Jul 2023 No recent reports of development identified for preclinical development in Malignant-melanoma in USA (Parenteral)
- 28 Jul 2023 No recent reports of development identified for preclinical development in Multiple-myeloma in USA (Parenteral)
- 12 Jul 2021 Preclinical development is still ongoing for Multiple myeloma in USA (Molecular Templates pipeline, July 2021)